We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Positive comment on coronavirus vaccine progress from Moderna's (MRNA) CEO during The Wall Street Journal's annual Tech Live conference has gained investors attention and raised vaccine optimism.
CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.
The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.
Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J. Gallagher (AJG) - as these are likely to see solid sales growth.
Gilead (GILD) gets positive CHMP opinion for KTE-X19, a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma.
The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.
ETFs overall gathered about $18.5 billion capital last week, bringing year-to-date inflows of $352.6 billion, ahead of the $211.7 billion seen at this same time a year ago.
Regeneron (REGN) gets positive CHMP opinion for Dupixent, recommending extending the approval in the European Union to include children aged 6 to 11 years with severe atopic dermatitis.
Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.
biotechs: Archive
Moderna Expects COVID-19 Vaccine Data in November: ETFs to Gain
by Sweta Jaiswal, FRM
Positive comment on coronavirus vaccine progress from Moderna's (MRNA) CEO during The Wall Street Journal's annual Tech Live conference has gained investors attention and raised vaccine optimism.
IBB XBI BBH BTEC IDNA GERM
biotechs etfs
CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.
VRTX CRSP ALNA ETON
biotechs
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates
by Zacks Equity Research
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
BIIB REGN GILD VRTX BSTC CRSP
biotechs pharmaceuticals
Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.
ALKS ALXN ALNY AMGN
biotechs
Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag
by Zacks Equity Research
The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.
SRPT SELB ALNA ETON
biotechs
Biogen (BIIB) Q3 Earnings Top, Tecfidera Generics Hurt Sales
by Zacks Equity Research
Biogen (BIIB) beats third-quarter estimates for both earnings and sales. Tecfidera generics hurts sales, resulting in guidance cut.
BIIB JNJ RHHBY MYL
biotechs
Fortress Biotech (FBIO) Enters Oversold Territory
by Zacks Equity Research
Fortress Biotech (FBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
FBIO
biotechs medical
Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
PFE MRK EXEL BMY
biotechs
Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M
by Zacks Equity Research
Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.
ENDP VRTX NVAX BSTC
biotechs
Aptose (APTO) Initiates Phase I a/b Study in Leukemia Patients
by Zacks Equity Research
Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.
RHHBY EBS ABBV APTO
biotechs
Aptinyx (APTX) Surges on Promising Stress Disorder Study Data
by Zacks Equity Research
Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.
JNJ PFE GSK APTX
biotechs
Bet on These 5 Top-Ranked Stocks With Strong Sales Growth
by Swayta Shah
Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J. Gallagher (AJG) - as these are likely to see solid sales growth.
MMM PKI SWK VRTX AJG
biotechs computers finance industrial-products insurance multi-sector-conglomerates pharmaceuticals
Gilead's (GILD) CAR T Cell Therapy Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead (GILD) gets positive CHMP opinion for KTE-X19, a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma.
REGN GILD NVS VRTX
biotechs
5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.
MRK GSK BMY VRTX SGEN
biotechs pharmaceuticals
Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.
AZN RHHBY MRK BMY
biotechs
Weekly ETF Roundup: Broad U.S. Equity Tops, Biotech Flops
by Sweta Killa
ETFs overall gathered about $18.5 billion capital last week, bringing year-to-date inflows of $352.6 billion, ahead of the $211.7 billion seen at this same time a year ago.
JNJ PFE LLY JNK QQQ HYG EFA IWM XBI VTI KRE VXUS FTCS ONLN
biotechs etfs finance retail
Regeneron's (REGN) Dupixent Gets Positive CHMP Opinion for Dermatitis
by Zacks Equity Research
Regeneron (REGN) gets positive CHMP opinion for Dupixent, recommending extending the approval in the European Union to include children aged 6 to 11 years with severe atopic dermatitis.
REGN SNY EBS CSTL
biotechs
Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran
by Zacks Equity Research
Alnylam (ALNY) gets positive opinion from the CHMP for lumasiran for the treatment of primary hyperoxaluria type 1.
REGN ALNY NVS EBS
biotechs
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports third-quarter earnings.
BIIB RHHBY MRK VRTX
biotechs
3 MedTech Growth Stocks to Scoop Up Ahead of Q3 Earnings
by Zacks Equity Research
Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.
EW RMD QGEN LHCG IDXX
biotechs medical
Eiger (EIGR) Up on Positive Results From Coronavirus Study
by Zacks Equity Research
Eiger (EIGR) gains on positive results from the ILIAD study on peginterferon lambda-1a (lambda) in outpatients with mild-to-moderate COVID-19.
REGN MRK BMY EIGR
biotechs
Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study
by Zacks Equity Research
Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.
AVEO EBS ARMP CSTL
biotechs
AnaptysBio (ANAB) Jumps: Stock Rises 7.7%
by Zacks Equity Research
AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
QGEN ANAB
biotechs medical
5 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
DQ HRI SURF CSTL CVLG
basic-materials biotechs medical transportation
PDL BioPharma Enters Oversold Territory
by Zacks Equity Research
PDL BioPharma has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
PDLI
biotechs medical